Currently Viewing:
Newsroom
Currently Reading
Patterns of Prescribed Opioid Use After Surgery Linked to Prescription Size, Study Says
November 16, 2018 – Alison Rodriguez
Estrogen Receptor Levels Lead to Discovery of Third Luminal Cell Population
November 16, 2018 – Samantha DiGrande
Shortening Treatment Time Maintains Efficacy, Saves Costs in Hepatitis C
November 16, 2018 – Samantha DiGrande
Genetic Risk Score May be Effective for Predicting Migraine Response to Triptans
November 16, 2018 – Alison Rodriguez
Advocates Lambast Growing Number of Uninsured in Arkansas Due to Work Rules
November 16, 2018 – Allison Inserro
FDA Gives Speedy Approval to Brentuximab for Peripheral T-cell Lymphoma
November 16, 2018 – Allison Inserro
Mutant NPM1 Maintains Leukemic State via HOX Expression in AML
November 16, 2018 – Jackie Syrop
Nivolumab Plus Azacitidine Increased Response Rates in Patients With Relapsed AML
November 16, 2018 – David Bai, PharmD
Following Release From Incarceration, People Living With HIV Have Higher Mortality Rates Than General Population
November 16, 2018 – Jaime Rosenberg

MS Drug Reduces Risk of Disability Progression in Phase 3 Study

Alison Rodriguez
Long-term treatment of patients with secondary progressive multiple sclerosis (SPMS) with siponimod may reduce the risk of disability progression, according to findings of the phase 3 EXPAND study.
Long-term treatment of patients with secondary progressive multiple sclerosis (SPMS) with siponimod may reduce the risk of disability progression, according to findings of the phase 3 EXPAND study.

The study compared the results of a 3-year treatment with once daily oral siponimod (2 mg) versus placebo. The results, presented at the 70th American Academy of Neurology (AAN) Annual Meeting, revealed that siponimod treatment resulted in significant risk reduction in disability progression, which was sustained for 3 to 6 months.

"Siponimod's beneficial effect on preventing disability progression, independent from its reduction in relapse frequency, demonstrates that patients with secondary progressive MS could benefit from this treatment," said Bruce Cree, MD, PhD, MAS, clinical research director and associate professor, School of Medicine, University of California San Francisco. 

The estimated risk reduction for disability progression sustained at 3 months ranged from 14% to 20% compared with the placebo for nonrelapsing patients. Also, for disability sustained at 6 months, the estimated risk reduction ranged from 29% to 33%. 

"This is very exciting because many people diagnosed with relapsing-remitting MS [multiple sclerosis], the most common form of the disease, will ultimately transition to SPMS, where without effective new therapies, they experience gradual worsening of disability despite infrequent relapses," Cree said in a statement.

Siponimod was also beneficial for cognitive processing speed—the key cognitive function affected by MS, according to the research. In the analysis, siponimod’s effect was measured by the Symbol Digit Modalities Test (SDMT), the Paced Auditory Serial Addition Test (PASAT), and the Brief Visuospatial Memory Test-Revised (BVMT-R). 

The results demonstrated that from baseline to month 24, treatment with siponimod had a significant benefit on cognitive processing speed compared with placebo, for all patients. Also, those who had relapsed within 2 years before starting the trial and those who did not also exemplified a cognitive benefit. Siponimod treatment, however, did not result in any significant differences in memory, according to the study.

"A decline in the ability to rapidly process information affects more than half of MS patients and is more severe in secondary progressive MS than relapsing-remitting MS. These data show that siponimod could have a meaningful impact on these patients' daily lives," said Danny Bar-Zohar, global head of Neuroscience Development, Novartis. "Furthermore, the advanced models used in the new analyses help us to better understand the relationship between relapses and disability and the effect of siponimod on these parameters,” 

Reference

Kappos L, Bar-Or A, Cree BAC; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6.

Related Articles

Expert Perspective on Evolving Diagnostic and Therapeutic Strategies in Multiple Sclerosis With Ben Thrower, MD
A Payer Point of View on the Changing Multiple Sclerosis Treatment Spectrum, With Kenneth Snow, MD
Updated Clinical Trial Results and Approval Progress for MS Ocrelizumab Treatment
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!